Sign up
Pharma Capital

Arecor appoints ex-IXICO CFO Susan Lowther as its new finance chief

Lowther’s first foray into the pharma and biotech sector was with US giant Monsanto, after which she has gone on to work for smaller industry players such as Novacyt, BioWisdom and, more recently, IXICO
abacus
Lowther has been appointed to the board with effect from 4 March

Diabetes drug developer Arecor has appointed Susan Lowther as its new chief financial officer.

Lowther has “significant experience” in the life sciences industry, Arecor said, having previously been the finance boss of AIM-listed IXICO PLC (LON:IXI) until December last year.

She has also been the chief bean counter for French cancer diagnostics specialist Novacyt, RiboTargets and BioWisdom, a data analysis firm which was acquired by Instem PLC (LON:INS) back in 2011.

WATCH: Accor strengthens team with appointment of experienced CFO

Lowther started her career at British Gas before moving on to work for US biotech giant Monsanto.

“I am delighted that Susan is joining the Arecor team,” said chief executive Sarah Howell.

“She brings a depth of financial and business expertise that will help us to deliver our ambitious growth plans.

“Following the completion of our successful capital raise last year we are well positioned to leverage our proprietary formulation platform in the development of our clinical products and in technology partnerships with pharmaceutical or biotechnology companies.”

Lowther added: “This is an exciting time to join Arecor and become part of an innovative and ambitious team.”



Register here to be notified of future ARECO Company articles
View full ARECO profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.